Azalactam compounds as HPK1 inhibitors

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, —N(R5)(R6), or (C3-C6)cycloalkyl, wherein said (C1-C6)alkyl, halo(C1-C6)alkyl, and (C3-C6)cycloalkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, (C1-C6)alkyl, or (C1-C6)alkoxy, wherein:
• R5 and R6 are each independently hydrogen or (C1-C6)alkyl that is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, (C1-C6)alkoxy, cyano, and hydroxy, or
• R5 and R6 taken together with the nitrogen to which they are attached form a (4- to 8-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, and halo(C1-C6)alkoxy;
• R2 is N(R7)(R8), wherein:
• R7 and R8 are each independently hydrogen or (C1-C6)alkyl that is substituted with 0, or 1 substituent that is halogen, (C1-C6)alkoxy, cyano, or hydroxy;
• or
• R7 is hydrogen or (C1-C6)alkyl that is substituted with 0, or 1 substituent that is halogen, (C1-C6)alkoxy, cyano, or hydroxy;
• and R8 taken together with the nitrogen to which it is attached and taken together with R3a and the carbon to which it is attached form a (4- to 6-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from halogen, hydroxy, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy, and halo(C1-C6)alkoxy;
• or
• R7 and R8 taken together with the nitrogen to which they are attached form a (4- to 6-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from halogen, hydroxy, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, and halo(C1-C6)alkoxy;
• R3a is hydrogen, or (C1-C3)alkyl that is substituted with 0 or 1 substituent that is hydroxy, or (C1-C3)alkoxy;
• R3b is hydrogen, or (C1-C3)alkyl, provided that R3a and R3b are not both H when R4 is (R4-i);
• R4 is (R4-i) or (R4-ii):
• wherein:
• R4N is (C1-C6)alkyl, halo(C1-C6)alkyl, or (C3-C6)cycloalkyl, wherein said (C1-C6)alkyl is substituted with 0 or 1 substituent that is hydroxy;
• R4C is hydrogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, or (C3-C6)cycloalkyl, wherein said (C1-C6)alkyl and halo(C1-C6)alkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (C1-C6)alkoxy;
• R4D is hydrogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, or (C3-C6)cycloalkyl, wherein said (C1-C6)alkyl and halo(C1-C6)alkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (C1-C6)alkoxy;
• R4E is hydrogen, halogen, cyano, hydroxy, or (C1-C6)alkyl;
• and
• R4F is hydrogen, halogen, cyano, hydroxy, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, or (C3-C6)cycloalkyl, wherein said (C1-C6)alkyl and halo(C1-C6)alkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (C1-C6)alkoxy.